CD274 and neoplasm: Based on this approach, a novel recombinant humanized PD‐L1/CTLA‐4 bispecific single‐domain antibody‐Fc fusion protein (KN046) was designed to bind to both PD‐L1 and CTLA‐4 and effectively enhance the killing of tumor cells.